Medical Therapy for PFO with TIA When Closure is Denied

Primary Recommendation

The Canadian Stroke Best Practice Guidelines recommend either antiplatelet or anticoagulant therapy for secondary stroke prevention in patients aged 60 years or younger with PFO-attributed stroke/TIA who do not undergo closure 1, 2, 3, 4, 5
The American Heart Association/American Stroke Association guidelines state that antiplatelet therapy is reasonable as the primary recommendation, with warfarin reserved for high-risk patients who have other indications for oral anticoagulation 6, 7

The American Heart Association recommends choosing antiplatelet therapy when there is no evidence of deep vein thrombosis or pulmonary embolism, no underlying hypercoagulable state identified, patient preference favors avoiding anticoagulation monitoring, and lower bleeding risk profile desired 6, 7, 1
The American Heart Association recommends choosing anticoagulation when evidence of venous thromboembolism is present, documented hypercoagulable state exists, and individual risk-benefit assessment favors anticoagulation 6, 7, 1, 2

The guidelines consistently reference single antiplatelet therapy or anticoagulation, not dual antiplatelet therapy, for PFO-associated stroke/TIA 1, 6, 2, 3, 4, 5

The Canadian Stroke Best Practice Guidelines recommend confirming the TIA diagnosis with positive neuroimaging or cortical symptoms, and evaluating for underlying hypercoagulable states or venous thrombosis 1, 3, 5, 6, 7

The American Heart Association/American Stroke Association recommends starting with single antiplatelet therapy unless specific indications for anticoagulation exist, which aligns with the highest quality guideline recommendations and minimizes bleeding risk 6, 7, 1, 2
The American Heart Association/American Stroke Association recommends switching to anticoagulation if recurrent ischemic events occur on antiplatelet therapy, venous thromboembolism is subsequently identified, or hypercoagulable workup reveals a prothrombotic condition 6, 7